INTRODUCTION
Halichondrin B (HB) is a structurally-complex marine natural product (1, 2) . Although HB's potent anticancer activity (2) (3) (4) led to interest by the U.S. National Cancer Institute in developing it as a novel chemotherapeutic, supply of HB from aquaculture prevented such efforts (5) .
Fortunately, HB's synthesis in 1992 by Kishi and colleagues (6) (7) (8) , together with discovery that its activity resides in its macrocyclic C1-C38 moiety 1 (5, 7, 9, 10) provided both a renewable material source and allowed simplification and optimization. Over 200 analogs of HB's C1-C38 moiety were made (5) , culminating in discovery of two promising analogs, C35-hydroxyl ER-076349 2 and C35-amine eribulin 3 (10; Figure 1 ). Eribulin is in Phase III clinical trials for advanced metastatic breast cancer and in Phase II trials for other cancer types. Clinically, eribulin is administered using intermittent dosing, 4 consistent with preclinical indications that it is maximally efficacious when dosed intermittently (11).
Eribulin works via apoptosis-inducing, microtubule-targeting antimitotic mechanisms (10, 12) involving inhibition of microtubule dynamics by mechanisms distinct from most other tubulintargeting agents (13) (14) (15) . Eribulin's mechanistic novelty is noteworthy when considering the original mechanistic studies on HB, which showed it to have a spectrum of biochemical effects Insights into this came from cell cycle analyses following drug treatment and washout, which revealed that mitotic blockade by eribulin was irreversible after drug washout, whereas ER-076349's blockade was reversible (5, 17) . While differences in mitotic block reversibility would be inconsequential under continuous exposure conditions in typical cell growth inhibition assays, we hypothesized that they might have considerable impact on in vivo efficacy under intermittent dosing conditions in preclinical xenograft models.
Here we present a cell-based assay allowing quantification of mitotic block reversibility of antimitotic agents under drug treatment and washout conditions. This assay was designed to be an in vitro cell-based surrogate for effects of intermittent dosing in vivo. Using eribulin and ER-076349, we explored relationships between mitotic block reversibility, long-term cell viability, inactivation of Bcl-2 and cellular uptake and retention of radiolabeled probes. Our results provide a plausible explanation for the in vivo superiority of eribulin relative to the more potent ER-076349. More generally, our results argue for consideration of cell-based pharmacodynamics 7 from thaw, or more than 30 passages from receipt from ATCC. DNA profile authentication of all 4 lines has been reported by ATCC; additionally, ATCC reports cytogenetic analyses and/or isoenzyme characterization for HeLa S3, HL-60 and Jurkat cells. No further cell line authentication was performed beyond what was provided by ATCC.
Cell cycle analysis
Aliquots of cell suspensions taken at t = 0 h and t = 10 h in the mitotic block reversibility assay were analyzed by flow cytometry as previously described (10) .
Mitotic block reversibility assay
Schematic representation of the mitotic block reversibility assay is shown in Figure 2 . U-937 cells were plated in 22.5 mL volumes in 75 cm 2 flasks at 1 × 10 5 cell/mL and incubated for 30-34 h to allow resumption of log-phase growth. 6 Test compounds were added as 2.5 mL of 10x concentrates yielding 0.1-1,000 nM final concentrations 7 in half-log increments; compound-free plates received 2.5 mL of vehicle control. This time point, designated t = -12 h, marked the beginning of the 12 h pretreatment period; previous studies had shown that 12 h exposure of U-937 cells to antimitotic agents provides optimal balance between full collection of cells in G2/M and minimal apoptosis induction (10, 12) . At t = 0 h, cells were harvested and washed twice with 50 mL pre-warmed, pre-5% CO 2 equilibrated, compound-free media using centrifugation at 300xg for 10 min, followed by resuspension in 35 mL of the same media; 10 mL aliquots were 6 Optimal time for resuming log-phase growth determined empirically. 7 1-10,000 nM used for colchicine, colcemid, nocodazole due to lower intrinsic growth inhibitory potencies.
8 immediately taken for cell cycle evaluation, with the remaining 25 mL returned to fresh flasks for 10 h incubation in compound-free media. At t = 10 h, 10 mL aliquots were taken from flasks for cell cycle evaluation, with immediate replenishment using 10 mL of fresh, pre-warmed, The timing of each step of the U-937 mitotic block reversibility assay was empirically determined based on thorough investigation of cell cycle phase lengths with and without cell synchronization. We had previously determined that the most accurate way of measuring mitotic completion was not by quantifying loss of cells from G2/M, but rather by measuring cells in the G1 phase at any given time, for the following reasons. Previous studies with bromo-deoxyuridine pulse-labeling established G1 phase length in log-phase U-937 cells to be ~8 h (Supplemental Figure S1 ). In addition, mitotic synchrony studies of U-937 cells using the highly reversible mitotic blocker nocodazole indicated that after nocodazole release, progression of cells through mitosis and into the G1 phase was complete by 10 h. Cells measured in the G1 peak thus represented cells which had completed mitosis during the previous 10 h (Supplemental Figure   S2 ). The G1 peak method of measuring mitotic completion was found to be superior to quantifying decreases in the G2/M peak itself; this method was thus selected for quantifying mitotic completion in the mitotic block reversibility assay. Based on analysis of 289 mitotic block reversibility assays, a complete mitotic block (CMB) is considered one in which no more than ~1% of cells are present in the G1 phase. 8 Mitotic block reversibility ratios were calculated by dividing the minimum drug concentration required to maintain CMB at t = 10 h by the minimum concentration required to initially induce CMB at t = 0 h.
The mitotic block reversibility assay involves numerous handling steps (add compounds, perform washouts, take aliquots, etc.) that have the potential to cause decreases in media temperature and CO 2 saturation levels that can slow cell cycle progression through different phases, markedly degrading data quality. In our experience, successful use of this assay depends on starting with log-phase cells, working fast at each step, using pre-warmed media for washing, minimizing cap opening times and times outside of incubators, and not opening incubator doors during incubations. Attempts to reduce the assay scale from 75 cm 2 flasks to 25 cm 2 flasks consistently led to degradation of data quality, an observation we attribute to accelerated loss of temperature stability and CO 2 equilibrium with smaller flasks and media volumes.
Bcl-2 phosphorylation
Cell aliquots were obtained at t = 0 h and t = 10 h during the mitotic block reversibility assay. To rule out cell type-specific effects, mitotic block reversibility studies were performed in Jurkat acute T cell leukemia, HL-60 promyelocytic leukemia and HeLa cells (Supplemental Figure S3) .
Results from all 3 lines showed that blockade by ER-076349 is reversible, whereas eribulin's blockade is irreversible. We conclude that ER-076349's reversibility and eribulin's irreversibility are compound-specific, cell type-independent characteristics.
Mitotic block reversibility of other tubulin-targeted agents
To test the generality of the mitotic block reversibility concept, reversibility assays were performed with paclitaxel, vinblastine, vincristine, colchicine, colcemid and nocodazole. Results are presented in Table 1 , along with data from the eribulin and ER-076349 studies of Figure 4 . As already noted, eribulin and ER-076349 were irreversible and moderately reversible mitotic blockers (reversibility ratios: 1 and 12, respectively). Paclitaxel was moderately reversible, (reversibility ratio: 14). Interestingly, vinblastine and vincristine showed widely different reversibility behaviors (reversibility ratios: 65 and 1, respectively); vincristine is thus an irreversible mitotic blocker, like eribulin. Similarly, while colchicine was almost completely irreversible (reversibility ratio: 1.7), colcemid was highly reversible (reversibility ratio: >100).
Nocodazole was also highly reversible (reversibility ratio: >100), consistent with its common use as a mitotic synchronizing agent. Overall, results of this survey of tubulin-targeted agents suggest that mitotic block reversibility profiles are unique, quantifiable, and compound-specific characteristics of individual compounds. Importantly, even small structural changes in compounds within a given class can lead to profound differences in mitotic block reversibility (e.g., eribulin versus ER-076349, vincristine versus vinblastine, colchicine versus colcemid).
Mitotic block reversibility and Bcl-2 phosphorylation
Since previous studies showed close correlations between Bcl-2 phosphorylation and eribulininduced apoptosis (12) , relationships between eribulin and ER-076349 mitotic block reversibility and Bcl-2 phosphorylation were assessed ( Figure 5 ). Bcl-2 phosphorylation was not detected in untreated U-937 cells at 0 h or 10 h. At 0 h (after 12 h pretreatment), Bcl-2 phosphorylation was seen with 0.3 nM ER-076349 and 3 nM eribulin and all higher concentrations of both drugs. In parallel with differences in mitotic block reversibility, maintaining Bcl-2 phosphorylation 10 h post-washout required 10 nM ER-076349 (33-fold higher than 0 h), whereas 3 nM eribulin both Similar results were seen with the radiolabeled vincas: only minimal losses of irreversible 9 Empirically-determined minimum time needed for maximal cell-associated radioactivity.
Phosphorylation-dependent inactivation of anti-apoptotic Bcl-2 following prolonged activation of the mitotic spindle checkpoint has been implicated in apoptosis induced by antimitotic agents (21) (22) (23) (24) . Previous studies showed that eribulin-induced Bcl-2 phosphorylation tracks closely with apoptosis induction (12) . The current studies extend this by showing that the reversibility of Bcl-2 phosphorylation mimics mitotic block reversibility for eribulin and ER-076349, providing a link between mitotic block reversibility differences and different long-term effects on viability.
Thus, sustained Bcl-2 phosphorylation following eribulin's irreversible mitotic block maintains inactivation of Bcl-2's anti-apoptotic effects, leading to apoptosis and complete loss of long-term viability at 5 days post-washout.
Results from [ While the basis for differences in drug uptake and post-washout retention is unknown, two potential explanations come to mind. First, this may simply reflect differential efflux via Pglycoprotein or related transporters. However, this seems unlikely for several reasons. First, the P-glycoprotein blocking agent verapamil (25) has no effect on uptake and post-washout retention of either [ Figure S4) . Second, eribulin and ER-076349 show similar susceptibilities to P-glycoprotein-mediated efflux (17), arguing against Pglycoprotein as the source of the two drugs' different behaviors. Third, any transporter with sufficiently high selectivity for eribulin to result in lower accumulation would be expected to drive enhanced post-washout efflux, yet the opposite was found: eribulin was more persistently retained compared to ER-076349. Based on these considerations, it seems unlikely that differential transporter selectivity for eribulin and ER-076349 can account for observed differences in mitotic block reversibility, drug uptake and post-washout retention.
Another possible explanation involves different tubulin binding characteristics. Our studies showed correlations between reversibility, drug uptake and post-washout retention for halichondrin analogs eribulin and ER-076349 and vinca alkaloids vinblastine and vincristine.
With respect to the halichondrins, Smith et al. (15) showed that eribulin binds predominantly to a small number of high affinity sites on microtubule plus ends, with earlier work from that group arguing against significant binding to microtubule sides based on eribulin's lack of effect on microtubule shortening (13) . Moreover, eribulin binds microtubule ends with ~10-fold greater potency than soluble tubulin heterodimers (15) Eribulin and ER-076349 data same as in Figure 4 on 
